Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic saline with continuous vs intermittent furosemide for intracranial pressure reduction
IRCT20170903036041N7Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of furosemide and hypertonic saline in intracranial hypertension (IH) and traumatic brain injury (TBI) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Intracranial pressure, Sodium and 5 more. Started Oct 2025; status: completed.
02
Drugs
furosemidehypertonic saline
03
Conditions
intracranial hypertension (IH)traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20170903036041N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170903036041N7.